Mastering Clozapine: An Updated Guide to Initiation, Monitoring, and Management

Tuesday, August 11, 2026, 5:45 PM - 7:15 PM CT, Springdale, AR

Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia. Unfortunately, it is grossly underutilized in our state. This lecture is designed to build confidence in the safe and effective use of clozapine for treatment-refractory schizophrenia. This session will combine real-world clinical expertise from an experienced psychiatrist, along with lived experience perspectives, to highlight both the therapeutic impact and challenges of clozapine treatment. Participants will receive a comprehensive review of clozapine, including its indications, common adverse effects, and essential steps in pretreatment evaluation and informed consent. The lecture will emphasize evidence-based approaches to safe titration, therapeutic drug level interpretation, and required initial and ongoing monitoring. Attendees will also learn to identify and manage clinically significant drug interactions and implement evidence-based strategies for side effect management. Designed to be interactive, the session will conclude with a Q&A to address common clinical dilemmas and enhance prescriber confidence in optimizing clozapine therapy.

AMA Credit Designation Statement

The University of Arkansas for Medical Sciences designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit Designation Statement

The University of Arkansas for Medical Sciences designates this live activity for a maximum of 1.5 ANCC contact hours.  Nursing contact hours will be awarded for successful completion of program components based upon documented attendance and completion of evaluation materials.

AAPA Credit Designation Statement

The University of Arkansas for Medical Sciences has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

1. Identify appropriate indications for clozapine use.
2. Apply evidence-based strategies to initiate, titrate, and monitor clozapine therapy.
3. Evaluate personal prescribing practices and barriers to clozapine use in order to increase confidence and expand appropriate utilization in clinical practice.

AMA PRA Category 1 Credits™ (1.50 hours), AAPA - American Academy of PAs Category 1 CME (1.50 hours), ANCC - American Nurses Credentialing Center (1.50 hours), Non-Physician AMA PRA Category 1 Credits™ (1.50 hours)

In support of improving patient care, University of Arkansas for Medical Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Mitigation of Relevant Financial Relationships

University of Arkansas for Medical Sciences Office of Continuing Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.